The varicose veins treatment market is evolving beyond cosmetic concerns, with a growing focus on addressing chronic venous insufficiency (CVI), a serious condition linked to leg ulcers, blood clots, and reduced quality of life. This shift reflects a broader medical emphasis on holistic care, where treating varicose veins is seen as a preventive measure against CVI and its complications. As awareness grows, demand for CVI-specific treatments is surging, driving market innovation and growth.

CVI affects 1 in 5 adults over 65 (NIH, 2023), making older patients a key demographic. Treatments like RFA and EVLT, which target underlying vein dysfunction, are now prioritized for CVI patients over sclerotherapy, which primarily addresses visible veins. A 2024 study in the Phlebology Journal found that RFA reduced CVI symptoms (swelling, pain) by 60% in 6 months, compared to 35% for sclerotherapy. This has led to a 30% increase in RFA device demand since 2022.

Manufacturers are responding with CVI-focused innovations. [CVI Solutions] developed a dual-mode device combining EVLT with pressure sensors to monitor vein closure efficacy in real time, ensuring optimal results for CVI patients. [AblatePlus]’s RFA system includes post-procedure tracking software, allowing doctors to monitor symptom improvement over time and adjust care plans. These tools not only enhance outcomes but also justify higher costs by demonstrating long-term value.

However, CVI treatment remains underdiagnosed. Only 50% of CVI patients seek treatment, often dismissing symptoms as age-related. Clinics are addressing this with targeted campaigns, such as [VeinHealthNow]’s “ Legs That Hurt, Legs That Heal” initiative, educating patients on CVI risks. For businesses aiming to tap into CVI-driven demand, the Varicose Veins Treatment Market CVI Impact Report by Market Research Future offers data on CVI prevalence, treatment preferences, and educational strategies, ensuring alignment with patient health priorities.